-
公开(公告)号：US07241873B2
公开(公告)日：2007-07-10
申请号：US10489866
申请日：2002-09-25
申请人： Toshimitsu Uede , Shigeyuki Kon , Nobuchika Yamamoto , Hirofumi Higuchi , Masaharu Torikai , Yoshiyuki Tokieda , Toshihiro Nakashima , Hiroaki Maeda
发明人： Toshimitsu Uede , Shigeyuki Kon , Nobuchika Yamamoto , Hirofumi Higuchi , Masaharu Torikai , Yoshiyuki Tokieda , Toshihiro Nakashima , Hiroaki Maeda
CPC分类号： C07K14/52 , A61K39/00 , A61K2039/505 , C07K16/24 , C07K16/2842 , C07K16/2848 , C07K2317/34
摘要： A recombinant antibody in which at least the constant regions in the heavy chain and the light chain have been converted into human-origin regions and which inhibits the binding of an integrin recognizing the RGD sequence to osteopontin or its fragment and inhibits the binding of an integrin recognizing the SVVYGLR sequence or a sequence corresponding thereto to osteopontin or its fragment. This antibody is useful as a remedy for autoimmune diseases and a remedy for rheumatism or rheumatoid arthritis. Thus, a method of treating autoimmune diseases, rheumatism or rheumatoid arthritis is provided. This osteopontin antibody is useful in a diagnostic for rheumatism and a method of diagnosing rheumatism too.
摘要翻译： 重组抗体，其中至少重链和轻链中的恒定区已转化为人源区，并且抑制识别RGD序列的整联蛋白与骨桥蛋白或其片段的结合并抑制整联蛋白的结合 识别SVVYGLR序列或与骨桥蛋白或其片段相应的序列。 该抗体可用作自身免疫性疾病的补救剂和风湿病或类风湿性关节炎的治疗剂。 因此，提供了治疗自身免疫疾病，风湿病或类风湿性关节炎的方法。 该骨桥蛋白抗体可用于风湿病的诊断和风湿病的诊断方法。
-
公开(公告)号：US20060002923A1
公开(公告)日：2006-01-05
申请号：US10489866
申请日：2002-09-25
申请人： Toshimitsu Uede , Shigeyuki Kon , Nobuchika Yamamoto , Hirofumi Higuchi , Masaharu Torikai , Yoshiyuki Tokieda , Toshihiro Nakashima , Hiroaki Maeda
发明人： Toshimitsu Uede , Shigeyuki Kon , Nobuchika Yamamoto , Hirofumi Higuchi , Masaharu Torikai , Yoshiyuki Tokieda , Toshihiro Nakashima , Hiroaki Maeda
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C07K16/28 , C12N5/06
CPC分类号： C07K14/52 , A61K39/00 , A61K2039/505 , C07K16/24 , C07K16/2842 , C07K16/2848 , C07K2317/34
摘要： A recombinant antibody in which at least the constant regions in the heavy chain and the light chain have been converted into human-origin regions and which inhibits the binding of an integrin recognizing the RGD sequence to osteopontin or its fragment and inhibits the binding of an integrin recognizing the SVVYGLR sequence or a sequence corresponding thereto to osteopontin or its fragment. This antibody is useful as a remedy for autoimmune diseases and a remedy for rheumatism or rheumatoid arthritis. Thus, a method of treating autoimmune diseases, rheumatism or rheumatoid arthritis is provided. This osteopontin antibody is useful in a diagnostic for rheumatism and a method of diagnosing rheumatism too.
摘要翻译： 重组抗体，其中至少重链和轻链中的恒定区已转化为人源区，并且抑制识别RGD序列的整联蛋白与骨桥蛋白或其片段的结合并抑制整联蛋白的结合 识别SVVYGLR序列或与骨桥蛋白或其片段相应的序列。 该抗体可用作自身免疫性疾病的补救剂和风湿病或类风湿性关节炎的治疗剂。 因此，提供了治疗自身免疫疾病，风湿病或类风湿性关节炎的方法。 该骨桥蛋白抗体可用于风湿病的诊断和风湿病的诊断方法。
-
公开(公告)号：US20110014213A1
公开(公告)日：2011-01-20
申请号：US12810939
申请日：2008-12-26
申请人： Masaharu Torikai , Daisuke Ishikawa , Toshihiro Nakashima , Hirofumi Higuchi , Fumihiko Sakai , Nobuchika Yamamoto , Hirotada Fujita , Katsunari Taguchi
发明人： Masaharu Torikai , Daisuke Ishikawa , Toshihiro Nakashima , Hirofumi Higuchi , Fumihiko Sakai , Nobuchika Yamamoto , Hirotada Fujita , Katsunari Taguchi
CPC分类号： C07K16/2839 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/52 , C07K2317/622 , C07K2317/92 , C07K2319/00
摘要： The present invention provides a human anti-α9 integrin antibody or an antibody fragment which specifically recognize human α9 integrin and mouse α9 integrin, inhibit interaction with their ligands, particularly, the antibody or antibody fragment which recognize loop regions of human and mouse α9 integrins, a gene encoding the antibody or antibody fragment, a recombinant expression vector containing the gene, a transformant harboring the gene, production method of human anti-α9 integrin antibody or antibody fragment using the transformant, and an agent for the prophylaxis or treatment of rheumatoid arthritis which contains the antibody or antibody fragment.
摘要翻译： 本发明提供一种人抗α9整联蛋白抗体或特异性识别人α9整联蛋白和小鼠α9整联蛋白的抗体片段，抑制与其配体的相互作用，特别是识别人和小鼠α9整联蛋白环区的抗体或抗体片段， 编码抗体或抗体片段的基因，含有该基因的重组表达载体，携带该基因的转化体，使用该转化体的人抗α9整联蛋白抗体的制备方法或抗体片段，以及预防或治疗类风湿性关节炎 其含有抗体或抗体片段。
-
公开(公告)号：US20090053212A1
公开(公告)日：2009-02-26
申请号：US11755671
申请日：2007-05-30
申请人： Nobuchika Yamamoto , Fumihiko Sakai , Hirofumi Higuchi , Masaharu Torikai , Toshihiro Nakashima
发明人： Nobuchika Yamamoto , Fumihiko Sakai , Hirofumi Higuchi , Masaharu Torikai , Toshihiro Nakashima
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/56
摘要： The present invention provides a humanized anti-human osteopontin antibody having better activities (antigen binding activity, leukocyte migration inhibitory activity and the like) and/or stability (resistance to heat, low-pH conditions, denaturants and the like) than those of conventional anti-human osteopontin antibodies.
摘要翻译： 本发明提供具有比常规的更好的活性（抗原结合活性，白细胞迁移抑制活性等）和/或稳定性（耐热，低pH条件，变性剂等）的人源化抗人骨桥蛋白抗体 抗人骨桥蛋白抗体。
-
公开(公告)号：US08715655B2
公开(公告)日：2014-05-06
申请号：US12810939
申请日：2008-12-26
申请人： Masaharu Torikai , Daisuke Ishikawa , Toshihiro Nakashima , Hirofumi Higuchi , Fumihiko Sakai , Nobuchika Yamamoto , Hirotada Fujita , Katsunari Taguchi
发明人： Masaharu Torikai , Daisuke Ishikawa , Toshihiro Nakashima , Hirofumi Higuchi , Fumihiko Sakai , Nobuchika Yamamoto , Hirotada Fujita , Katsunari Taguchi
IPC分类号： A61K39/395 , C07K16/00 , C07K16/46 , C07K16/28 , G01N33/53
CPC分类号： C07K16/2839 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/52 , C07K2317/622 , C07K2317/92 , C07K2319/00
摘要： The present invention provides a human anti-α9 integrin antibody or an antibody fragment which specifically recognize human α9 integrin and mouse α9 integrin, inhibit interaction with their ligands, particularly, the antibody or antibody fragment which recognize loop regions of human and mouse α9 integrins, a gene encoding the antibody or antibody fragment, a recombinant expression vector containing the gene, a transformant harboring the gene, production method of human anti-α9 integrin antibody or antibody fragment using the transformant, and an agent for the prophylaxis or treatment of rheumatoid arthritis which contains the antibody or antibody fragment.
摘要翻译： 本发明提供一种人抗α9整联蛋白抗体或特异性识别人α9整联蛋白和小鼠α9整联蛋白的抗体片段，抑制与其配体的相互作用，特别是识别人和小鼠α9整联蛋白环区的抗体或抗体片段， 编码抗体或抗体片段的基因，含有该基因的重组表达载体，携带该基因的转化体，使用该转化体的人抗-α9整联蛋白抗体的制备方法或抗体片段，以及预防或治疗类风湿性关节炎 其含有抗体或抗体片段。
-
公开(公告)号：US07807161B2
公开(公告)日：2010-10-05
申请号：US11755671
申请日：2007-05-30
申请人： Nobuchika Yamamoto , Fumihiko Sakai , Hirofumi Higuchi , Masaharu Torikai , Toshihiro Nakashima
发明人： Nobuchika Yamamoto , Fumihiko Sakai , Hirofumi Higuchi , Masaharu Torikai , Toshihiro Nakashima
IPC分类号： A61K39/00 , A61K39/395 , C07K16/46 , C07K16/24
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/56
摘要： The present invention provides a humanized anti-human osteopontin antibody having better activities (antigen binding activity, leukocyte migration inhibitory activity and the like) and/or stability (resistance to heat, low-pH conditions, denaturants and the like) than those of conventional anti-human osteopontin antibodies.
摘要翻译： 本发明提供具有比常规的更好的活性（抗原结合活性，白细胞迁移抑制活性等）和/或稳定性（耐热，低pH条件，变性剂等）的人源化抗人骨桥蛋白抗体 抗人骨桥蛋白抗体。
-
公开(公告)号：US08603476B2
公开(公告)日：2013-12-10
申请号：US12812341
申请日：2009-01-09
申请人： Kenji Uehara , Hirofumi Higuchi , Toshihiro Nakashima , Daisuke Ishikawa , Nobuchika Yamamoto , Hirotada Fujita , Fumihiko Sakai
发明人： Kenji Uehara , Hirofumi Higuchi , Toshihiro Nakashima , Daisuke Ishikawa , Nobuchika Yamamoto , Hirotada Fujita , Fumihiko Sakai
IPC分类号： A61K39/395
CPC分类号： C07K16/2839 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides a humanized anti-human α9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human α9 integrin antibody, namely, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human α9 integrin in the pathogenesis, which uses the antibody.
摘要翻译： 本发明提供与供体小鼠抗人α9整联蛋白抗体相比具有改善的活性和/或性质的人源化抗人α9整联蛋白抗体，即包含重链可变区的人源化抗人α9整联蛋白抗体，其包含 的SEQ ID NO：11所示的氨基酸序列和由SEQ ID NO：17所示的氨基酸序列组成的轻链可变区，含有重链可变区的人源化抗人α9整联蛋白抗体包含由 由SEQ ID NO：13所示的氨基酸序列和由SEQ ID NO：17所示的氨基酸序列组成的轻链可变区，含有重链可变区的人源化抗人α9整联蛋白抗体 由SEQ ID NO：15所示的氨基酸序列和由SEQ ID NO：9所示的氨基酸序列组成的轻链可变区，以及预防或治疗涉及 人类α9整联蛋白在发病机制中使用抗体。
-
公开(公告)号：US20110059077A1
公开(公告)日：2011-03-10
申请号：US12812341
申请日：2009-01-09
申请人： Kenji Uehara , Hirofumi Higuchi , Toshihiro Nakashima , Daisuke Ishikawa , Nobuchika Yamamoto , Hirotada Fujita , Fumihiko Sakai
发明人： Kenji Uehara , Hirofumi Higuchi , Toshihiro Nakashima , Daisuke Ishikawa , Nobuchika Yamamoto , Hirotada Fujita , Fumihiko Sakai
CPC分类号： C07K16/2839 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides a humanized anti-human α9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human α9 integrin antibody, namely, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human α9 integrin in the pathogenesis, which uses the antibody.
摘要翻译： 本发明提供与供体小鼠抗人α9整联蛋白抗体相比具有改善的活性和/或性质的人源化抗人α9整联蛋白抗体，即包含重链可变区的人源化抗人α9整联蛋白抗体，其包含 的SEQ ID NO：11所示的氨基酸序列和由SEQ ID NO：17所示的氨基酸序列组成的轻链可变区，含有重链可变区的人源化抗人α9整联蛋白抗体由 由SEQ ID NO：13所示的氨基酸序列和由SEQ ID NO：17所示的氨基酸序列组成的轻链可变区，包含由SEQ ID NO：17所示的重链可变区组成的人源化抗人α9整联蛋白抗体 由SEQ ID NO：15所示的氨基酸序列和由SEQ ID NO：9所示的氨基酸序列组成的轻链可变区，以及用于预防或治疗涉及人α9整数的各种疾病的手段 rin在发病机制中，其使用抗体。
-
公开(公告)号：US20110014193A1
公开(公告)日：2011-01-20
申请号：US12812368
申请日：2009-07-09
申请人： Kenji Uehara , Hirofumi Higuchi , Toshihiro Nakashima , Daisuke Ishikawa , Nobuchika Yamamoto , Hirotada Fujita , Fumihiko Sakai
发明人： Kenji Uehara , Hirofumi Higuchi , Toshihiro Nakashima , Daisuke Ishikawa , Nobuchika Yamamoto , Hirotada Fujita , Fumihiko Sakai
CPC分类号： C07K16/2839 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides a humanized anti-human α9 integrin antibody having improved activity and/or property as compared to donor mouse anti-human α9 integrin antibody, namely, a humanized anti-human α9 integrin antibody comprising a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 1 or the amino acid sequence shown by SEQ ID NO: 1 wherein one or several amino acids are substituted, deleted, inserted and/or added and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 61 or the amino acid sequence shown by SEQ ID NO: 61 wherein one or several amino acids are substituted, deleted, inserted and/or added, as well as a means for preventing or treating various diseases involving human α9 integrin in their pathogenesis, which uses the antibody.
摘要翻译： 本发明提供了与供体小鼠抗人α9整联蛋白抗体相比具有改善的活性和/或性质的人源化抗人α9整联蛋白抗体，即人源化抗人α9整联蛋白抗体，其包含由以下组成的重链可变区： SEQ ID NO：1所示的氨基酸序列或SEQ ID NO：1所示的氨基酸序列，其中一个或几个氨基酸被取代，缺失，插入和/或添加，以及由氨基酸组成的轻链可变区 SEQ ID NO：61所示的酸序列或SEQ ID NO：61所示的氨基酸序列，其中一个或几个氨基酸被取代，缺失，插入和/或添加，以及用于预防或治疗涉及 人α9整合素在其发病机制中，其使用抗体。
-
公开(公告)号：US20110117602A1
公开(公告)日：2011-05-19
申请号：US12743739
申请日：2008-11-18
申请人： Yuji Ito , Masanori Baba , Naomichi Arima , Yasuo Suda , Toshihiro Nakashima , Masaharu Torikai
发明人： Yuji Ito , Masanori Baba , Naomichi Arima , Yasuo Suda , Toshihiro Nakashima , Masaharu Torikai
CPC分类号： C07K16/005 , C07K16/2833 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , G01N33/57484
摘要： A human antibody that has a specific reactivity with multiple tumor cell lines including ATL cells and possesses both safety and therapeutic efficacy and a fragment of said antibody are provided. A human antibody and a fragment of said antibody that may recognize HLA-DR β chain expressed on the surface of tumor cells were obtained. In particular, it was found that a dimer of scFv (diabody) of said antibody may induce potent apoptosis in cells expressing the HLA-DR β chain. The antibody and a fragment of said antibody obtained in accordance with the present invention are useful for a detection reagent, a diagnostic and a medicament for protection or treatment of cancers including ATL and/or viral infectious diseases.
摘要翻译： 提供了与多种肿瘤细胞系（包括ATL细胞）具有特异性反应性并具有安全性和治疗功效以及所述抗体片段的人类抗体。 可以识别HLA-DR和bgr的人抗体和所述抗体的片段; 获得在肿瘤细胞表面表达的链。 特别地，发现所述抗体的scFv（双抗体）的二聚体可能在表达HLA-DR和bgr的细胞中诱导有效的凋亡; 链。 根据本发明获得的抗体和所述抗体的片段可用于检测试剂，诊断剂和用于保护或治疗包括ATL和/或病毒感染性疾病的癌症的药物。
-
-
-
-
-
-
-
-
-
搜索结果
45 条记录 (耗时 0.047 秒)